{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:57:11Z","timestamp":1790373431889,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,6,16]],"date-time":"2010-06-16T00:00:00Z","timestamp":1276646400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1007\/s00432-010-0917-5","type":"journal-article","created":{"date-parts":[[2010,6,15]],"date-time":"2010-06-15T12:19:15Z","timestamp":1276604355000},"page":"659-667","source":"Crossref","is-referenced-by-count":50,"title":["Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma"],"prefix":"10.1007","volume":"137","author":[{"given":"Beom Kyung","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Yong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Jin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hoon","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ja Kyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do Youn","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang-Hyub","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,6,16]]},"reference":[{"key":"917_CR1","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/cncr.10694","volume":"95","author":"E Ando","year":"2002","unstructured":"Ando E, Tanaka M, Yamashita F et al (2002) Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 95:588\u2013595","journal-title":"Cancer"},{"key":"917_CR2","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.1200\/JCO.2005.05.470","volume":"23","author":"L Bedenne","year":"2005","unstructured":"Bedenne L, Milan C, Pariente A et al (2005) Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol 23:4338\u20134346","journal-title":"J Clin Oncol"},{"key":"917_CR3","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","volume":"362","author":"J Bruix","year":"2003","unstructured":"Bruix J, Burroughs A, Llovet JM (2003) Hepatocellular carcinoma. Lancet 362:1907\u20131917","journal-title":"Lancet"},{"key":"917_CR4","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2008.18.8151","volume":"27","author":"SL Chan","year":"2009","unstructured":"Chan SL, Mo FK, Johnson PJ et al (2009) New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 27:446\u2013452","journal-title":"J Clin Oncol"},{"key":"917_CR5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25\u201334","journal-title":"Lancet Oncol"},{"key":"917_CR6","first-page":"3784","volume":"38","author":"E Frei","year":"1978","unstructured":"Frei E, Steele G, Come S et al (1978) A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2\u2032-deoxyuridine and 5-fluorouracil. Cancer Res 38:3784\u20133792","journal-title":"Cancer Res"},{"key":"917_CR7","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/annonc\/mdm528","volume":"19","author":"A Ganeshan","year":"2008","unstructured":"Ganeshan A, Upponi S, Hon LQ et al (2008) Hepatic arterial infusion of chemotherapy: the role of diagnostic and interventional radiology. Ann Oncol 19:847\u2013851","journal-title":"Ann Oncol"},{"key":"917_CR8","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"SG Gwyther","year":"2000","unstructured":"Gwyther SG, Christian MC, van Oosterom AT et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"917_CR9","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1440-1746.2008.05444.x","volume":"23","author":"KH Han","year":"2008","unstructured":"Han KH, Park JY (2008) Chemotherapy for advanced hepatocellular carcinoma. J Gastroenterol Hepatol 23:682\u2013684","journal-title":"J Gastroenterol Hepatol"},{"key":"917_CR10","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000112805","volume":"72","author":"M Ikeda","year":"2007","unstructured":"Ikeda M, Okusaka T, Ueno H et al (2007) Hepatic arterial infusion chemotherapy with epirubicin in patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis. Oncology 72:188\u2013193","journal-title":"Oncology"},{"key":"917_CR11","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.3748\/wjg.v13.i41.5465","volume":"13","author":"T Ishikawa","year":"2007","unstructured":"Ishikawa T, Imai M, Kamimura H et al (2007) Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur\/uracil: a pilot study. World J Gastroenterol 13:5465\u20135470","journal-title":"World J Gastroenterol"},{"key":"917_CR12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/jso.10116","volume":"80","author":"T Itamoto","year":"2002","unstructured":"Itamoto T, Nakahara H, Tashiro H et al (2002) Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. J Surg Oncol 80:143\u2013148","journal-title":"J Surg Oncol"},{"key":"917_CR13","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/S0959-8049(96)00266-3","volume":"32A","author":"PG Johnston","year":"1996","unstructured":"Johnston PG, Geoffrey F, Drake J et al (1996) The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line. Eur J Cancer 32A:2148\u20132154","journal-title":"Eur J Cancer"},{"key":"917_CR14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/1471-2407-6-121","volume":"6","author":"K Kobayashi","year":"2006","unstructured":"Kobayashi K, Tsuji A, Morita S et al (2006) A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma. BMC Cancer 6:121","journal-title":"BMC Cancer"},{"key":"917_CR15","first-page":"2620","volume":"5","author":"M Kurihara","year":"1999","unstructured":"Kurihara M, Shirasaka T, Matsukawa M et al (1999) Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves. Clin Cancer Res 5:2620\u20132628","journal-title":"Clin Cancer Res"},{"key":"917_CR16","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378\u2013390","journal-title":"N Engl J Med"},{"key":"917_CR18","first-page":"1719","volume":"23","author":"T Nakano","year":"2003","unstructured":"Nakano T, Ohmori S, Deguchi M et al (2003) Low-dose chemotherapy of cisplatin and 5-fluorouracil or doxorubicin via implanted fusion port for unresectable hepatocellular carcinoma. Anticancer Res 23:1719\u20131722","journal-title":"Anticancer Res"},{"key":"917_CR19","first-page":"88","volume":"10","author":"JW Park","year":"2004","unstructured":"Park JW (2004) Practice guideline for diagnosis and treatment of hepatocellular carcinoma. Korean J Hepatol 10:88\u201398","journal-title":"Korean J Hepatol"},{"key":"917_CR20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/cncr.22759","volume":"110","author":"JY Park","year":"2007","unstructured":"Park JY, Ahn SH, Yoon YJ et al (2007) Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 110:129\u2013137","journal-title":"Cancer"},{"key":"917_CR21","doi-asserted-by":"crossref","unstructured":"Pisani P, Ferlay J, Bray F et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74\u2013108","DOI":"10.3322\/canjclin.55.2.74"},{"key":"917_CR22","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1053\/j.gastro.2008.02.090","volume":"134","author":"KR Reddy","year":"2008","unstructured":"Reddy KR, Rudolph L, Marrero JA et al (2008) Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134:1752\u20131763","journal-title":"Gastroenterology"},{"key":"917_CR23","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1200\/JCO.2009.23.1282","volume":"27","author":"A Riaz","year":"2009","unstructured":"Riaz A, Ryu RK, Kulik LM et al (2009) Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol 27:5734\u20135742","journal-title":"J Clin Oncol"},{"key":"917_CR24","first-page":"807","volume":"24","author":"S Saji","year":"2004","unstructured":"Saji S, Sugiyama Y, Matsuo A et al (2004) Expression of p53 protein as a predictor of the response to 5-fluorouracil and cisplatin chemotherapy in human gastrointestinal cancer cell lines evaluated with apoptosis by use of thin layer collagen gel. Int J Oncol 24:807\u2013813","journal-title":"Int J Oncol"},{"key":"917_CR26","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","volume":"42","author":"M Sherman","year":"2005","unstructured":"Sherman M, Bruix J (2005) Management of hepatocellular carcinoma. Hepatology 42:1208\u20131236","journal-title":"Hepatology"},{"key":"917_CR27","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00280-009-0945-5","volume":"64","author":"AN Tse","year":"2009","unstructured":"Tse AN, Wu N, Patel D et al (2009) A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies. Cancer Chemother Pharmacol 64:935\u2013944","journal-title":"Cancer Chemother Pharmacol"},{"key":"917_CR28","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1634\/theoncologist.2009-0038","volume":"14","author":"SR Vora","year":"2009","unstructured":"Vora SR, Zheng H, Stadler ZK et al (2009) Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. Oncologist 14:717\u2013725","journal-title":"Oncologist"},{"key":"917_CR29","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00280-009-1126-2","volume":"65","author":"HY Woo","year":"2010","unstructured":"Woo HY, Bae SH, Park JY et al (2010) A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 65:373\u2013382","journal-title":"Cancer Chemother Pharmacol"},{"key":"917_CR30","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s00535-004-1494-7","volume":"40","author":"T Yamasaki","year":"2005","unstructured":"Yamasaki T, Kimura T, Kurokawa F et al (2005) Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. J Gastroenterol 40:70\u201378","journal-title":"J Gastroenterol"},{"key":"917_CR31","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1872-034X.2008.00338.x","volume":"38","author":"M Yoshikawa","year":"2008","unstructured":"Yoshikawa M, Ono N, Yodono H et al (2008) Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res 38:474\u2013483","journal-title":"Hepatol Res"},{"key":"917_CR32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1634\/theoncologist.2008-0281","volume":"14","author":"AX Zhu","year":"2009","unstructured":"Zhu AX, Clark JW (2009) Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy. Oncologist 14:67\u201369","journal-title":"Oncologist"},{"key":"917_CR33","doi-asserted-by":"crossref","first-page":"350","DOI":"10.6004\/jnccn.2009.0027","volume":"7","author":"AX Zhu","year":"2009","unstructured":"Zhu AX, Yen Y, Goff LW et al (2009) NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw 7:350\u2013391","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-010-0917-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-010-0917-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-010-0917-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T03:29:28Z","timestamp":1559186968000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-010-0917-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,16]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["917"],"URL":"https:\/\/doi.org\/10.1007\/s00432-010-0917-5","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,16]]}}}